APPENDIX 1: WORKSHOP PROGRAMME
PROGRAMME DAY 1: THURSDAY, 12TH NOVEMBER
Open to all ECETOC member companies and invited guests
10:30-11:00 Registration and coffee
11:00-11;10 Welcome and Introduction Alan Poole
ECETOC SG, Belgium
Session 1
Level Setting: Reproductive Toxicity Studies and Epigenetic Studies
11:10-11:40 What are reproductive toxicity guideline studies? Jessica LaRocca
Why are they conducted? What can they achieve? Dow, USA
Where are the gaps?
11:40-12:00 What are epigenetic studies? John Greally
Technical aspects and data interpretation to achieve Albert Einstein College of
confidence in epigenetic studies (human Medicine, Yeshiva University, USA
epidemiology and animal-based studies)
12:00-12:20 Effects on rat reproductive development produced by Paul Foster
antiandrogens: upstream indicators of downstream effects NIEHS, USA
12:20-12:40 Effects on rat reproductive development produced by Earl Gray
antiandrogens: AOPs and transgenerational effects EPA, USA
12:40-13:00 The lack of Transgenerational Inheritance of Anti- Roland Buesen
androgenic effects after Vinclozolin Treatment BASF, Germany
13:00-14:00 Lunch
14:00-14:20 The potential application of microRNAs in regulatory toxicology Emma Marczylo
Public Health, England
14:20-14:40 Introduction of Percellome Project, highlighting the concept of Jun Kanno
"signal toxicity". Case study: Single exposure adult studies and NIHS, Japan
developmental cases, at signal dose levels, i.e. at the level of
No overt cytotoxicity or organ toxicity monitorable by histopathology
Session 2
Understand the Relationship between Epigenetic Change and Adverse Endpoints
14:40-15:00 What are the general principles for indicating whether the epigenetic Bob Chapin
change is causal (adverse) or adaptive? Pfizer Inc, USA
15:00-15:20 Practical experience with rodent species used in toxicology studies: Richard Meehan
what is a normal epigenetic background? Medical Research Council, UK
15:20-15:40 Determining clear and robust biomarkers of epigenetic change Daniele Fallin
and adversity Johns Hopkins University, USA
15:40-16:00 Scoping Discussion: Can we start to identify key biomarkers Tim Gant/Miriam Jacobs
and potential mechanisms associated with the phenotypic CRCE, UK
adverse change? (sound techniques, robust data interpretation
procedures)
16:00-16:20 The concept of "repeated exposure" and possible links to epigenetic Jun Kanno
regulations. Repeated dose studies introducing baseline responses NIHS, Japan
and transient responses with possible link to epigenetics
16:20-17:00 Zebrafish Model – applications to address what is relevant for Peter Aleström
multiple generational studies Norwegian University of Life
Sciences, Oslo, Norway
17:00-17:20 How can these be applied to current regulatory test paradigms? Ioanna Katsiadaki
CEFAS Weymouth Laboratory, UK
17:20-17:40 Consensus on what and how? Tim Gant/Miriam Jacobs
CRCE, UK
17:40-18:00 Closure and guidance for Day 2 Alan Poole
ECETOC SG, Belgium
18:30-20:00 Networking cocktail for Day 2 participants
PROGRAMME DAY 2: FRIDAY, 13TH NOVEMBER
INVITED EXPERTS ONLY
08:30-08:45 Registration and coffee
11:00-11;10 Welcome and Objectives for the day Alan Poole
Instructions for Breakouts ECETOC SG, Belgium
09:10-11:15 Breakout Topic 1:
Develop a Roadmap for the Practical Use of Epigenetic Studies
to Underpin Regulatory Applications
Topic 1 Epigenetic Design Studies: Moderator: Miram Jacobs
45 minutes Relevance to Regulatory Applications? Rapporteur: Jessica LaRocca
Topic 2 How to Design Epigenetic Studies? Moderator: John Greally
45 minutes Rapporteur: Madeleine Laffont
Topic 3 What is necessary to interpret Epigenetics Moderator: Roland Buesen
45 minutes in light of Reprotoxocity Studies Rapporteur: Kamin Johnson
11:15-11:45 Coffee Break
11:45-13:00 Plenary: Breakout Conclusions Moderators
13:00-14:00 Lunch
Breakout Topic 2:
Generating a Prioritised Research Agenda
14:00-15:30 Generate Prioritised Research Agenda
15:30-16:30 Plenary: Breakout Conclusions Rapporteurs
16:30-17:00 Summary and Closure Alan Poole
ECETOC SG, Belgium